Biostage (BSTG) Releases Earnings Results

Biostage (OTCMKTS:BSTG) issued its quarterly earnings data on Thursday. The company reported ($0.37) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.28), reports.

Shares of BSTG traded down $0.10 during midday trading on Friday, reaching $3.20. 206 shares of the company were exchanged, compared to its average volume of 1,457. Biostage has a 1-year low of $0.60 and a 1-year high of $5.85.

ILLEGAL ACTIVITY WARNING: This news story was published by WKRB News and is the sole property of of WKRB News. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at

Biostage Company Profile

Biostage, Inc, a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan organ implants. It is developing bioengineered organ implants, which addresses the damage of the esophagus, bronchus, and trachea due to cancer, infection, trauma, or congenital abnormalities.

Featured Article: Stock Selection – What is cash flow?

Earnings History for Biostage (OTCMKTS:BSTG)

Receive News & Ratings for Biostage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostage and related companies with's FREE daily email newsletter.

Leave a Reply